Lilly’s Covid-19 antibody combo EUA expands for post-exposure prophylaxis
The authorisation comes after the US Government resumed the supply of bamlanivimab and etesevimab together.
Divya Tirumalaraju
Latest articles
All Articles
Covis Group to acquire AMAG Pharmaceuticals for $647m
Covis Group has agreed to acquire biopharmaceutical company AMAG Pharmaceuticals for a total consideration of about $647m, or $13.75…
Gilead and Eisai obtain Japanese approval for RA drug Jyseleca
Gilead Sciences and Eisai have received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for Jyseleca…
Novartis faces delay in expansion of SMA drug Zolgensma indication
Novartis has faced delay in expansion of indication for its spinal muscular atrophy (SMA) drug Zolgensma (onasemnogene abeparvovec) after…
Sanofi and GSK sign Covid-19 vaccine supply deal with Canada
Sanofi and GlaxoSmithKline (GSK) have signed a deal with the Government of Canada to supply up to 72 million…
Fujifilm to seek approval for Avigan in Covid-19 after positive data
Japan's Fujifilm Toyama Chemical plans to seek approval for its anti-viral drug Avigan (favipiravir) to treat patients with Covid-19,…
Scenic Biotech forms drug development alliance with Genentech
Scenic Biotech has entered into a multi-year strategic partnership with Roche unit Genentech in a bid to discover, develop…
Bausch Health to acquire ophthalmology assets of Allegro
Bausch Health has signed an agreement to acquire an option to buy biopharmaceutical company Allegro Ophthalmics’ ophthalmological assets.
Samsung Biologics signs $330m deal to produce AstraZeneca’s therapies
South Korea-based biopharmaceutical services provider Samsung Biologics has signed a long-term supply agreement, valued at approximately $330.8m, with AstraZeneca.